- Global Pharma News & Resources

Pre-filled Hemostasis Agents Market Insights, Deep Analysis of Key Vendor in the Industry 2022-2031

According to the latest research by FMI, pre-filled hemostasis agents market is set to witness a 6.8 % growth during the year 2021-2031. Hemostasis is a major challenge, primarily in surgical procedures and trauma. Hemostasis agents are primarily in the form of fibrinogen concentrate, dried plasma, dried and synthetic platelets, tranexamic acid and topical hemostatic products.

The use of pre-filled hemostatic agents in pre-hospital trauma through combat or in civilian settings has led to a reduction in preventable deaths due to hemorrhage. This is one of the prime factors driving the growth and demand. Apart from this, the pre-filled hemostatic agents are ready to use and do not require on-site mixing or pre-application preparation.

The property of biocompatibility and low cost and ease of use of these agents have resulted in increased adoption in combat fields as well as a gradual adoption in pre-hospital trauma. These factors are expected to improve the product adoption, as well as demand during the forecast period.

Request a Sample of this Report @

What is Driving Demand for Pre-filled Hemostasis Agents?

The key factors which drive the demand for the pre-filled hemostasis agents are the increasing number of surgical procedures like orthopedic procedures with respect to hip and knee replacement and hernia operations. Apart from these, the rise in the number of geriatric population and the prevalence of wounds and injuries associated with that have led to increased adoption of pre-filled hemostasis agents. The use of hemostasis agents in the field of cardiovascular surgery procedures for the efficient management of bleeding has also effectuated the application of the pre-filled hemostasis agents.

Which Factors are Likely to Augment Growth of Pre-filled Hemostasis Agents?

The advancement in technology in reference to the hemostatic agents and their applications in the field of medicine has aided patients with emergency assistance to prevent hemorrhage. The increasing growth of chronic diseases and injuries, high risk associated with heart diseases and birth defects and research apropos of disorders such as hemophilia also increase value of pre-filled hemostasis agents.

Global prevalence of diabetes is expected to reach 366 million by 2030 with current prevalence as 26.9% of population with age group of 65 and over and about 60% have cancer. Overall of 8-18% patients with cancer suffer from diabetes. This correlation is effectively justifiable in cases of diabetes induced cardiovascular risk. Hemostatic agents are thus effective during potential bleeding complications and hence expected to augment to the demand surge over the forecast period.

US and Canada Pre-Filled Hemostasis Agents Outlook

The US dominates the global pre-filled hemostasis agents in terms of value. The growth is attributed to the increasing demand of surgical procedures in the North America region. In 2018, a record of about 210,454 people over the world suffered from hemophilia and out of those, about 18,008 people belonged to the US. The rising prevalence of bleeding disorders in North America has led to the adoption of hemostasis agents for bleeding management. Apart from this, the rising geriatric population in both US and Canada has attributed to wound and injury, as well as the advent of chronic diseases such as heart disorders and diabetes.

Europe Demand Outlook for Pre-filled Hemostasis Agents

The Europe pre-filled hemostasis agents application is experiencing an increase in the previously dormant initiation of the use of hemostasis agents during post-partum hemorrhage. According to the German Post-Partum Hemorrhage guidelines, the procedures for controlled bleeding management includes the use of pre-filled hemostasis agents, especially with patients suffering from hemophilia or von Willebrand disease. Germany thus holds a key share in the Europe pre-filled hemostasis agent application.

Ask An Analyst @

Who are the Key Manufacturers and Suppliers of Pre-filled Hemostasis Agents?

The key manufacturers in the pre-filled hemostasis agents production and sales are

  • Baxter International Inc.
  • Pfizer Inc.
  • Advance Medical Solutions Group
  • Integra Life Sciences Corporation
  • CryoLife, Inc.
  • Medtronic Plc
  • Equimedical
  • Vascular Solutions, Inc.
  • C.R. Bard Incorporation
  • Z-Medica Corporation
  • Nihon Kohden
  • Sanyo Chemical Industries, Ltd.
  • hangzhou singclean medical products co. ltd
  • Johnson and Johnson Services Inc
  • Mallinckrodt Plc
  • Gelita GmbH
  • Z-Medica LLC.

The key players of pre-filled hemostasis agents follow the strategy of mergers, acquisitions and R&D investments and tie-ups with hospitals.

Pre-filled Hemostasis Agents market Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint
Key Segments

By Type:

  • Sealants
  • Hemostats
  • Adhesives

By Treatment:

  • Obstetrics
  • Cardiovascular
  • Neurosurgery
  • Digestive Surgery
  • General Surgery
  • Others

By End User:

  • Hospitals
  • Surgical Centers
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • China
  • Japan
  • South Korea
  • Middle East and Africa

Buy Complete Report @

Contact Us:                                                            

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries:
For Media Enquiries:

Editor Details

Last Updated: 02-Feb-2022